Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? (Q43760681)

26 November 2017

Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? (English)

1 reference

primary biliary cholangitis

26 November 2017

0 references

author name string

Corpechot C

1

1 reference

26 November 2017

Benlian P

2

1 reference

26 November 2017

Barbu V

3

1 reference

26 November 2017

Chazouillères O

4

1 reference

26 November 2017

Poupon RE

5

1 reference

26 November 2017

Poupon R

6

1 reference

26 November 2017

1 September 2001

1 reference

26 November 2017

Journal of Hepatology

1 reference

26 November 2017

35

1 reference

26 November 2017

3

1 reference

26 November 2017

324-328

1 reference

Familial primary biliary cirrhosis

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Prevalence and pattern of familial disease in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Familial primary biliary cirrhosis in Hiroshima

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Impact of apo E phenotype on the regulation of cholesterol metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Effect of human apolipoprotein E isoforms on plasma lipids, lipoproteins and apolipoproteins in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Apolipoprotein E polymorphism in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

The geoepidemiology of primary biliary cirrhosis: contrasts and comparisons with the spectrum of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

The LXRs: a new class of oxysterol receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

Cholesterol absorption and metabolism and LDL kinetics in healthy men with different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900137-4

7 January 2021

10.1016/S0168-8278(01)00137-4

Identifiers

DOI

1 reference

26 November 2017

1 reference